Biopharmaceutical Contract Manufacturing Market Drivers, Restraints, Potential Growth Opportunities, Trends and Forecast 2018-2026

Contract manufacturing organizations (CMOs) provide wide range of manufacturing services, which include contract packaging, quality testing, and development service to pharmaceutical and biotechnology industries. Biopharmaceutical companies prefer CMOs due to complexity in manufacturing process of biomolecules, as they consists of different shape, size, and behavior with significantly complex process than pharmaceutical drugs. 

Download PDF Brochure Of This Research Report @ www.coherentmarketinsights.com/insight/request-pdf/1077

Contract manufacturing organizations provide services from development of biologics to commercial scale production. Few companies also provide cell line development, fermentation, process optimization, and analytical characterization. Improved efficiency, weak product pipeline, and increasing price pressure is expected to favor the growth of biopharmaceutical contract manufacturing market in near future.

Increasing outsourcing services in biopharmaceutical industry is expected to fuel the growth of biopharmaceutical contract manufacturing market:

Pelican Therapeutics and subsidiary of Heat Biologics entered into a manufacturing agreement with KBI Biopharma in September, 2017. As per the agreement, KBI biopharma will provide development and manufacturing service under biopharmaceutical contract development and manufacturing organization (CDMO) for cGMP production of an antibody (PTX-35) and a fusion protein (PTX-15). Pelican Therapeutics intends to develop immunotherapy drugs by mimicking the production of antigen-specific T-cells. In May 2016, pelican received grant around US$ 15.2 million by Cancer Prevention and Research Institute of Texas (CPRIT) to its manufacturing efforts in immunotherapies for lung, pancreatic, lymphoma, prostate, and ovarian cancers.

Ajinomoto Althea, Inc., announced a GMP production suite in newly established High Potency Products (HPP) manufacturing site located in San Diego, California, in September 2017. Currently, Althea is offering process development and analytical services to the clients and from November 2017, the company will provide facilities for GMP manufacturing of bioconjugation and complex formulation. Apart from this services, Althea is aiming to provide full manufacturing services including fill-and-finish, which will start off in 2018.

Key Players:

The key players in biopharmaceutical contract manufacturing market include 
• Lonza Group Ltd., 
• ProBioGen AG, 
• Boehringher Ingelheim, 
• BIOMEVA GmbH, 
• Celonic GmbH, 
• Sandoz, 
• Fujifilm Diosynth Biotechnology, 
• Rentschler Biotechnologie.

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1077

Global Biopharmaceutical Contract Manufacturing Market Taxonomy:

On the basis of contract type, product type, and therapeutic application, global biopharmaceutical contract manufacturing market is segmented into:

By Contract Type:
• Active Pharmaceutical Ingredient (API)
• Fill-And-Finished

By Product Type:
• Interferons
• Monoclonal Antibodies
• Recombinant Hormone
• Proteins
• Vaccines
• Vitamins
• Insulin
• Others

By Therapeutic Applications:
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Neurology
• Infectious Diseases
• Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: 

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.